0	5	Human	human	JJ
6	22	immunodeficiency	immunodeficiency	NN
23	28	virus	virus	NN
29	35	type-2	type-2	NN
36	40	gene	gene	NN
41	51	expression	expression	NN
51	52	:	:	:
53	56	two	two	CD
57	66	enhancers	enhancer	NNS
67	70	and	and	CC
71	76	their	their	PRP$
77	87	activation	activation	NN
88	90	by	by	IN
91	97	T-cell	t-cell	NN
98	108	activators	activator	NNS
108	109	.	.	.

111	114	The	the	DT
115	120	human	human	JJ
121	137	immunodeficiency	immunodeficiency	NN
138	145	viruses	virus	NNS
146	147	(	(	(
147	151	HIVs	HIV	NNP
151	152	)	)	)
153	156	may	may	MD
157	164	include	include	VB
165	166	a	a	DT
167	175	spectrum	spectrum	NN
176	178	of	of	IN
179	191	retroviruses	retrovirus	NNS
192	196	with	with	IN
197	204	varying	vary	VBG
205	214	potential	potential	NN
215	217	to	to	TO
218	224	infect	infect	VB
225	230	their	their	PRP$
231	235	host	host	NN
235	236	,	,	,
237	244	undergo	undergo	VBP
245	249	long	long	JJ
250	257	periods	period	NNS
258	260	of	of	IN
261	267	latent	latent	JJ
268	277	infection	infection	NN
277	278	,	,	,
279	282	and	and	CC
283	289	induce	induce	VB
290	299	pathology	pathology	NN
299	300	.	.	.

301	306	Since	since	IN
307	317	expression	expression	NN
318	320	of	of	IN
321	324	the	the	DT
325	332	viruses	virus	NNS
333	335	is	be	VBZ
336	338	in	in	IN
339	344	large	large	JJ
345	349	part	part	NN
350	359	regulated	regulate	VBN
360	362	by	by	IN
363	366	the	the	DT
367	375	sequence	sequence	NN
376	384	elements	element	NNS
385	387	in	in	IN
388	393	their	their	PRP$
394	398	long	long	JJ
399	407	terminal	terminal	JJ
408	415	repeats	repeat	NNS
416	417	(	(	(
417	421	LTRs	LTR	NNP
421	422	)	)	)
422	423	,	,	,
424	428	this	this	DT
429	434	study	study	NN
435	438	was	be	VBD
439	447	directed	direct	VBN
448	450	to	to	TO
451	453	an	an	DT
454	462	analysis	analysis	NN
463	465	of	of	IN
466	469	the	the	DT
470	480	regulatory	regulatory	JJ
481	489	elements	element	NNS
490	492	in	in	IN
493	496	the	the	DT
497	502	HIV-2	hiv-2	NN
503	506	LTR	ltr	NN
506	507	.	.	.

508	511	The	the	DT
512	517	HIV-2	hiv-2	NN
518	521	LTR	ltr	NN
522	525	was	be	VBD
526	531	found	find	VBN
532	534	to	to	TO
535	542	contain	contain	VB
543	546	two	two	CD
547	556	enhancers	enhancer	NNS
556	557	.	.	.

558	561	One	one	CD
562	564	of	of	IN
565	570	these	these	DT
571	580	enhancers	enhancer	NNS
581	583	is	be	VBZ
583	584	,	,	,
585	587	in	in	IN
588	592	part	part	NN
592	593	,	,	,
594	603	identical	identical	JJ
604	606	to	to	TO
607	610	the	the	DT
611	616	HIV-1	HIV-1	NNP
617	625	enhancer	enhancer	NN
625	626	.	.	.

627	631	This	this	DT
632	640	enhancer	enhancer	NN
641	643	in	in	IN
644	649	HIV-1	HIV-1	NNP
650	652	is	be	VBZ
653	656	the	the	DT
657	663	T-cell	t-cell	NN
664	674	activation	activation	NN
675	683	response	response	NN
684	691	element	element	NN
691	692	;	;	:
693	695	in	in	IN
696	701	HIV-2	hiv-2	NN
701	702	,	,	,
703	710	however	however	RB
710	711	,	,	,
712	714	it	it	PRP
715	717	is	be	VBZ
718	721	the	the	DT
722	728	second	second	JJ
729	737	enhancer	enhancer	NN
738	742	that	that	WDT
743	745	is	be	VBZ
746	752	mainly	mainly	RB
753	764	responsible	responsible	JJ
765	768	for	for	IN
769	779	activation	activation	NN
780	782	in	in	IN
783	791	response	response	NN
792	794	to	to	TO
795	801	T-cell	t-cell	NN
802	812	activators	activator	NNS
812	813	.	.	.

814	817	The	the	DT
818	824	second	second	JJ
825	833	enhancer	enhancer	NN
834	843	interacts	interact	VBZ
844	848	with	with	IN
849	852	two	two	CD
853	860	nuclear	nuclear	JJ
861	868	binding	bind	VBG
869	877	proteins	protein	NNS
878	879	(	(	(
879	881	85	85	CD
882	884	kD	kd	NN
885	888	and	and	CC
889	891	27	27	CD
892	894	kD	kd	NN
895	903	mobility	mobility	NN
903	904	)	)	)
905	909	that	that	WDT
910	916	appear	appear	VBP
917	919	to	to	TO
920	922	be	be	VB
923	931	required	require	VBN
932	935	for	for	IN
936	943	optimal	optimal	JJ
944	952	enhancer	enhancer	NN
953	961	function	function	NN
962	965	and	and	CC
966	976	activation	activation	NN
976	977	.	.	.

978	990	Observations	observation	NNS
991	995	such	such	JJ
996	998	as	as	IN
999	1004	these	these	DT
1005	1014	encourage	encourage	NN
1015	1018	the	the	DT
1019	1030	speculation	speculation	NN
1031	1035	that	that	IN
1036	1041	there	there	EX
1042	1045	may	may	MD
1046	1048	be	be	VB
1049	1055	subtle	subtle	JJ
1056	1067	differences	difference	NNS
1068	1070	in	in	IN
1071	1074	the	the	DT
1075	1085	regulation	regulation	NN
1086	1088	of	of	IN
1089	1094	HIV-1	HIV-1	NNP
1095	1098	and	and	CC
1099	1104	HIV-2	hiv-2	NN
1105	1115	expression	expression	NN
1116	1120	that	that	WDT
1121	1124	may	may	MD
1125	1127	be	be	VB
1128	1136	relevant	relevant	JJ
1137	1139	to	to	TO
1140	1143	the	the	DT
1144	1152	possible	possible	JJ
1153	1159	longer	long	JJR
1160	1167	latency	latency	NN
1168	1171	and	and	CC
1172	1179	reduced	reduce	VBN
1180	1193	pathogenicity	pathogenicity	NN
1194	1196	of	of	IN
1197	1202	HIV-2	hiv-2	NN
1202	1203	.	.	.